RA Capital-backed Oak Hill Bio plans to enter the Nasdaq through a SPAC merger with Research Alliance Corporation III, extending the rare-disease funding pipeline. The strategy is aimed at advancing Oak Hill’s genetic disease candidate with the capital infusion required for clinical development and manufacturing readiness. The transaction is framed around bringing a rare genetic program into public-market scrutiny while preserving runway for studies that are often capital-intensive but smaller in patient counts. For biotech investors, it reflects continued SPAC activity concentrated on targeted, genetically defined disease bets. Oak Hill’s move also underscores how investors are seeking differentiated mechanisms tied to clear patient subgroups as trial designs evolve toward precision enrollment.